gi-hepatology
Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading
CTCAE-based grading of immune-related colitis caused by checkpoint inhibitor immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4). Guides immunotherapy hold/discontinuation and corticosteroid management.
References
- Puzanov I et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.
- ESMO Clinical Practice Guidelines for the management of toxicities from immunotherapy. Ann Oncol. 2017;28(Suppl 4):iv119-iv142.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Pembrolizumab · Anti-PD-1 monoclonal antibody (immune checkpoint inhibitor)
- Atezolizumab · Anti-PD-L1 Monoclonal Antibody — Immune Checkpoint Inhibitor (Specialist Oncology Drug)
- Avelumab · Anti-PD-L1 Monoclonal Antibody — Immune Checkpoint Inhibitor (Specialist Oncology Drug)
- Pembrolizumab · PD-1 Immune Checkpoint Inhibitor
- Ipilimumab (Specialist drug) · Anti-CTLA-4 monoclonal antibody (immune checkpoint inhibitor)
- Nivolumab (Specialist drug) · Anti-PD-1 immune checkpoint inhibitor
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.